Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

Inclusion Criteria:

• LAR (ie, legal guardian or caregiver) must have signed and dated an IRB/IEC-approvedICF in accordance with regulatory, local, and institutional guidelines.

• Confirmed Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, TextRevision (DSM-5-TR) psychiatric diagnosis of 1 of the following:

1. Schizophrenia or schizoaffective disorder

2. Bipolar I or II disorder

3. Attention-deficit/hyperactivity disorder (ADHD)

4. Tourette's disorder

5. Autism spectrum disorder (ASD)

• Participant is judged by the investigator to be clinically stable (eg, nopsychiatric hospitalization within the last 6 months; no imminent risk of suicide orinjury to self, others, or property).

Exclusion Criteria:

• Any clinically significant neurological, metabolic (including type 1 diabetes),hepatic, renal, hematological, pulmonary, cardiovascular, GI (including activeobstructive GI disorders), carcinoma, active biliary disorders (eg, symptomaticgallstones) and/or urological disorder, congestive heart failure (uncontrolled), orCNS infection that would pose a risk to the participants if they were to participatein the study or that might confound the results of the study.

• Participant has a risk for suicidal behavior during the study, as determined by theinvestigator's clinical judgment and C-SSRS.

• eGFR < 60 mL/min.

• History of Gilbert's Disease or history of liver disease (Child-Pugh class A andhigher).

• History or high risk of urinary retention, gastric retention, or narrow-angleglaucoma.

• Participants with history of bladder stones or recurrent UTIs.

• Other protocol defined inclusion/exclusion criteria apply.